CLAIM #27351 · GILD (GILD) · 2025Q3 earnings call · Oct 30, 2025 · due Dec 31, 2026
“So we do believe it's going to be a gradual ramp-up. And then for us, it really sets up the platform for the ramp for Yeztugo in 2026.”
Johanna Mercier · Chief Commercial Officer
PENDING
graded after results covering Dec 31, 2026 are reported
How to check this claim
Look at: Yeztugo (lenacapavir for PrEP) net product sales, quarterly and full-year
It came true if: 2026 full-year Yeztugo net sales higher than 2025 full-year net sales, with quarter-over-quarter revenue increasing through 2026
Where: Gilead Sciences quarterly earnings release / 10-K and 10-Q product revenue disclosures
Verify independently
SEC filings for GILD ↗ · Claim quote is verbatim from the 2025Q3 earnings call.